The below mentioned growth stocks have witnessed a substantial increase in their share prices in the last one year. Let’s take a closer look at these stock-
Nanosonics Limited (ASX: NAN)
Nanosonics Limited (ASX: NAN) provides infection control solutions through its unique automated disinfection technology. On 5 February 2019, the company announced that it has appointed three new senior executives as part of its global business expansion plan. As per the release, the company hired Renee Salaberry as Chief Marketing Officer, David Morris as Chief Strategy Officer and Regional President Asia Pacific, and Rod Lopez as Chief Operating Officer.
In the last five years, the company’s annual sales have tripled, and the company is listed on ASX 200 with a market capitalization in the vicinity of a billion dollars. Nanosonics is the market leader in ultrasound reprocessing in Australia, whilst more than 90 percent of the company’s sales are exported to 19 countries. The company has successfully executed its business model, with a hybrid of direct and distributor sales in key markets such as the United States, France, Germany and the UK.
For FY 2018, the company reported EBITDA of $5.86 million, EBIT of $4.36 million. In FY 2018, the company reported operating profit after tax of $5.751 million. At the end of FY 2018, the company had cash and cash equivalent of $69.433 million.
In the last one year, the share price of the company increased by 24.01 percent as on 4 February 2019. NAN’s shares traded at $3.450 (-0.289% intraday) with a market capitalization of circa $1.04 billion as on 5 February 2019.
Volpara Health Technologies Limited (ASX: VHT)
Medical technology company, Volpara Health Technologies Limited (ASX: VHT) uses Artificial intelligence (AI) to improve its Quality of screening. The company is focused on the early detection of breast cancer. In Q3 FY 2019, the company reported Cash receipts from customers of NZ$1.9 Million. During Q3 FY 2019, the company added NZ$755,000 of ARR (Annual Recurring Revenue) and NZ$4.3 Million of TCV (Total Contract Value). The Company recently revised its gross margin calculation for a closer alignment with industry standards. The revised gross margin of 83 percent (vs. 84% in FY18) shows how the company’s business model continues to scale well.
According to the company’s CEO Dr. Ralph Highnam, the management of the company is pleased with the company’s consistently increasing cash inflow and revenues and other key metrics. However, the ARR numbers are behind where the company wanted to be at this point in the year. As per Dr. Ralph the shortfall is due to a combination of the effects of the confusion caused due to the introduction of GDPR in Europe in mid-2018; needing to do trials outside the US, the company’s US sales team taking time to get fully productive; and the time it’s taking to close some of the very big US screening organizations. Nonetheless, with record cash incomes, low churn, a strong sales pipeline, and an ever-more-educated sales force, the company is looking forward to a strong Q4 and ending the FY with a least 85% growth in ARR.
In the past one year, the share price of the company increased by 43.42% intraday as on 4 February 2019. VHT’s shares traded at $1.080 (-0.917% intraday) with a market capitalization of circa $195.49 million as on 5 February 2019.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.